Insulin Lispro: 5 agencies, 2007–2020
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused insulin lispro: all 6 decisive outcomes across 4 agencies were positive or positive with restrictions.
The file has been open for more than a decade: 12.6 years separate the first record, 7 Nov 2007 at PHARMAC (New Zealand), from the most recent, 10 Jun 2020 at HAS (France).
No assessment is on file from TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Nothing has been added since 2020; on this evidence the file is dormant.
1 of these 9 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
PHARMAC (New Zealand) was first to assess insulin lispro, on 7 Nov 2007; PBAC (Australia) did not open a file until 2017 — an unusually long tail of 9.7 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 6 years in total.
3 of the 5 agencies here assessed insulin lispro more than once, HAS (France) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed insulin lispro.
The full ledger for insulin lispro reads 6 recommended, 2 not assessed and 1 other.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 10 Jun 2020 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| AWMSG (Wales) | 22 Apr 2020 | Treatment of diabetes mellitus in adults | outside AWMSG criteria | source |
| PBAC (Australia) | 2017 | Diabetes mellitus | The PBAC recommended the listing of the new strength of insulin lispro Humalog U200 for th… | source |
| SMC (Scotland) | 13 Oct 2008 | for patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. | accepted | source |
| PHARMAC (New Zealand) | 7 Nov 2007 | Diabetes mellitus (Type I and II) | PTAC advice: Cost Neutral · decision reached | source |
4 further decisions for insulin lispro, across 3 agencies, are not shown here. They link to 4 further source documents.
Related molecules
- insulin glargine — same ATC class A10A — Diabetes
- insulin detemir — same ATC class A10A — Diabetes
- insulin aspart — same ATC class A10A — Diabetes
- insulin degludec — same ATC class A10A — Diabetes
- insulin glulisine — same ATC class A10A — Diabetes
- insulin glargine / lixisenatide — same ATC class A10A — Diabetes
Coverage: 9 decisions for insulin lispro from 5 agencies, 2007 to 2020. Data to 7 Sep 2026. ATC class A10A — Diabetes. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.